Zhejiang Aisong Pharmaceutical

Aisong Pharmaceutical is a clinical-stage biotechnology company based in Hangzhou, China, specializing in the development of small molecule drugs for metabolic and inflammatory diseases. The company's lead asset, AS001, is a selective thyroid hormone receptor beta (THR-beta) agonist designed to treat non-alcoholic steatohepatitis (NASH) and related metabolic disorders. Founded by industry veterans with experience at global pharmaceutical firms, Aisong focuses on high-value targets with validated mechanisms of action. The company has successfully raised significant venture capital from leading investors like Lilly Asia Ventures and Qiming Venture Partners to advance its pipeline through clinical development.